Analysts expect OKYO Pharma Ltd to report revenue of 0.00 for 2026, against a range of 0.00 to 0.00. The most recent reported year, 2025, came in at 0.00.
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | - | - | ||
| High Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 11.16 M | ||
| Low Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 10.14 M | ||
| Consensus Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 10.65 M |
Analysts expect OKYO Pharma Ltd to report earnings per share of -0.15 for 2026, against a range of -0.16 to -0.14. The most recent reported year, 2025, came in at -0.17, a 70.0% miss against the -0.10 consensus.
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.61 | -0.40 | -0.12 | -0.17 | - | - | ||
| High Estimate | 0.00 | -0.39 | -0.13 | -0.09 | -0.14 | -0.40 | ||
| Low Estimate | 0.00 | -0.47 | -0.15 | -0.11 | -0.16 | -0.44 | ||
| Consensus Estimate | 0.00 | -0.43 | -0.14 | -0.10 | -0.15 | -0.42 |